摘要
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC) with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in parallel, a phase 2 adaptive umbrella trial consisting of a criteria-fulfilled (CF) cohort and a compassionate use (CU) cohort under expanded eligibility criteria, and a prospective real-world study (RWS). Here, we present efficacy and safety data from 48 patients with treatment-naive, advanced HER2-mutant NSCLC treated with the pan-HER receptor tyrosine kinase inhibitor pyrotinib (CF and CU cohorts) or physician's therapy of choice (RWS cohort). In the phase 2 trial CF cohort (n = 28), the primary endpoint was reached with an objective response rate of 35.7% after pyrotinib treatment. Secondary endpoints included disease control rate (89.3%), median progression-free survival (PFS) (7.3 months), median overall survival (OS) (14.3 months) and toxicity, which was acceptable, with grade 3 or 4 treatment-related adverse events occurring in three patients (10.7%). The phase 2 trial CU cohort (n = 12) showed an objective response rate of 16.7%, disease control rate of 83.4%, median PFS of 4.7 months and median OS of 14.2 months after pyrotinib treatment. The RWS cohort (n = 8) had no responses to physician's therapy of choice, while median PFS and OS were 3.0 and 12.2 months, respectively. @@@ Treatment of patients with HER2-mutant non-small-cell lung cancer with the pan-HER inhibitor pyrotinib in a phase 2 trial or compassionate use showed a favorable objective response rate, whereas patients treated in parallel by physician's choice in a real-world study did not.
学科与关键词
- Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational studyLi, Yiqun; Tong, Zhongsheng; Wu, Xinhong; Ouyang, Quchang; Cai, Li; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Niu, Zhaofeng; Wang, Qitang; Xu, Binghe*International Journal of Cancer, 2023, 153(10): 1809-1818.
- Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyTu, Hai-Yan; Yin, Kai; Zhao, Xiaotian; Ke, E-E; Wu, Si-Pei; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Xu, Chong-Rui; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Zhou, Qing; Yang, Jin-Ji; Zhong, Wen-Zhao; Wang, Bing-Chao; Zhang, Xu-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-Long*Molecular Oncology, 2023, 17(8): 1581-1594.被引 1
- Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trialZheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong*; Wang, Xiaojia*Nature Communications, 2023, 14(1): 8314.
